24.52
price down icon3.69%   -0.94
pre-market  Pre-market:  25.05   0.53   +2.16%
loading
Intellia Therapeutics Inc stock is traded at $24.52, with a volume of 8.50M. It is down -3.69% in the last 24 hours and up +117.18% over the past month. Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$25.46
Open:
$25.62
24h Volume:
8.50M
Relative Volume:
1.56
Market Cap:
$2.63B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-4.4745
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+22.85%
1M Performance:
+117.18%
6M Performance:
+262.19%
1Y Performance:
+37.83%
1-Day Range:
Value
$23.22
$25.78
1-Week Range:
Value
$19.89
$26.98
52-Week Range:
Value
$5.90
$26.98

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Name
Intellia Therapeutics Inc
Name
Phone
857-285-6200
Name
Address
40 ERIE STREET, CAMBRIDGE, MA
Name
Employee
598
Name
Twitter
@intelliatweets
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NTLA's Discussions on Twitter

Compare NTLA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
24.52 2.73B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.79 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.46 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.63 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
796.92 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.10 36.88B 4.56B -176.77M 225.30M -1.7177

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-06-25 Upgrade Citizens JMP Mkt Perform → Mkt Outperform
Apr-21-25 Upgrade Wolfe Research Peer Perform → Outperform
Mar-05-25 Initiated H.C. Wainwright Buy
Feb-28-25 Downgrade Goldman Neutral → Sell
Feb-28-25 Downgrade JP Morgan Overweight → Neutral
Jan-27-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-23-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Apr-13-23 Initiated Canaccord Genuity Buy
Mar-21-23 Initiated Bernstein Outperform
Mar-14-23 Upgrade BMO Capital Markets Market Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Jan-24-23 Upgrade Citigroup Sell → Neutral
Jan-19-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-21-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Sell
Jun-17-22 Initiated BMO Capital Markets Market Perform
Jun-16-22 Initiated BofA Securities Buy
Apr-28-22 Initiated Credit Suisse Outperform
Feb-18-22 Initiated William Blair Outperform
Feb-07-22 Upgrade Oppenheimer Perform → Outperform
Jan-31-22 Initiated Cowen Outperform
Jan-07-22 Initiated Piper Sandler Overweight
Oct-05-21 Initiated Guggenheim Buy
Sep-24-21 Initiated Stifel Buy
Jun-28-21 Reiterated H.C. Wainwright Buy
Jun-11-21 Initiated H.C. Wainwright Buy
May-07-21 Upgrade ROTH Capital Neutral → Buy
May-04-21 Initiated RBC Capital Mkts Outperform
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-22-20 Downgrade Robert W. Baird Outperform → Neutral
Oct-27-20 Initiated Truist Buy
Oct-14-20 Initiated Wells Fargo Overweight
Sep-18-20 Initiated Goldman Buy
Feb-28-20 Upgrade Oppenheimer Perform → Outperform
Feb-14-20 Downgrade Wedbush Outperform → Neutral
Nov-01-19 Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19 Initiated Robert W. Baird Outperform
Jun-10-19 Initiated ROTH Capital Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Nov-02-18 Downgrade Wedbush Outperform → Neutral
Oct-29-18 Initiated Credit Suisse Neutral
Sep-21-18 Initiated Raymond James Mkt Perform
May-15-18 Upgrade Chardan Capital Markets Neutral → Buy
Mar-08-18 Initiated JMP Securities Mkt Outperform
Nov-01-17 Reiterated Jefferies Buy
Jun-22-17 Resumed Jefferies Buy
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-05-16 Upgrade Jefferies Hold → Buy
View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

pulisher
Oct 12, 2025

What Recent Gene Editing Breakthroughs Mean for the Future of Intellia Therapeutics Stock - Yahoo Finance

Oct 12, 2025
pulisher
Oct 12, 2025

Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment - Yahoo Finance

Oct 12, 2025
pulisher
Oct 12, 2025

A Look at Intellia Therapeutics’s Valuation Following Breakthrough ATTR Data and HAELO Study Milestone - Yahoo Finance

Oct 12, 2025
pulisher
Oct 12, 2025

Published on: 2025-10-12 05:21:21 - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Oct 12, 2025
pulisher
Oct 11, 2025

Will Intellia Therapeutics Inc. (38I) stock profit from automation wave2025 Fundamental Recap & AI Driven Stock Reports - newser.com

Oct 11, 2025
pulisher
Oct 10, 2025

CRISPR Market Size, Share, Recent Developments, Growth - openPR.com

Oct 10, 2025
pulisher
Oct 10, 2025

Using flow based indicators on Intellia Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics Hits New 52-Week High at $26.45 - Markets Mojo

Oct 09, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6% - MSN

Oct 09, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside - ts2.tech

Oct 09, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 09, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance

Oct 09, 2025
pulisher
Oct 09, 2025

Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Can Intellia Therapeutics Inc. (38I) stock test all time highsM&A Rumor & Safe Entry Point Identification - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - sharewise.com

Oct 08, 2025
pulisher
Oct 08, 2025

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook - ts2.tech

Oct 08, 2025
pulisher
Oct 08, 2025

Is Intellia Therapeutics Inc 38I a good long term investmentRetail Investor Activity & Actionable Entry & Exit Points Daily - earlytimes.in

Oct 08, 2025
pulisher
Oct 08, 2025

Intellia Therapeutics (NASDAQ:NTLA) Trading 6.6% HigherHere's What Happened - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Intellia Therapeutics (NTLA) Surges Over 23% in Market Trading - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

On Course: Intellia CSO Offers Clinical Update of In Vivo Gene Editing Therapies at ESGCT - Genetic Engineering and Biotechnology News

Oct 08, 2025
pulisher
Oct 08, 2025

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - AOL.com

Oct 08, 2025
pulisher
Oct 08, 2025

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - Yahoo Finance

Oct 08, 2025
pulisher
Oct 08, 2025

Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Oct 08, 2025
pulisher
Oct 07, 2025

Supercharged Gene-Editing: Intellia’s 63% Rally Just The Start, Say Analysts - NAI500

Oct 07, 2025
pulisher
Oct 07, 2025

Intellia Therapeutics Inc Stock Analysis and ForecastBear Market Strategies & Easy Tools to Analyze Your Investment Risk - earlytimes.in

Oct 07, 2025
pulisher
Oct 07, 2025

1 Stock Up by 63% This Year That Could Double, According to Wall Street - Yahoo Finance

Oct 07, 2025
pulisher
Oct 07, 2025

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com - Investing.com Canada

Oct 07, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NTLA) Sees Stock Rise Following Analyst U - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year High on Analyst Upgrade - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics stock hits 52-week high at 21.49 USD - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Citizens Jmp - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NASDAQ:NTLA) Upgraded by JMP Securities to Market Outperform Rating - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

JMP Securities Upgrades Intellia Therapeutics (NTLA) - Nasdaq

Oct 06, 2025
pulisher
Oct 06, 2025

What Analysts Are Saying About Intellia Therapeutics Stock - Benzinga

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NTLA) Upgraded by JMP Securities to Marke - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Published on: 2025-10-06 06:23:31 - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Intellia Therapeutics (NTLA) Sees Strong Gains as Ark Invest Inc - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Cathie Wood's Ark Invest weekly recap: adds more Alibaba, Baidu, Kodiak AI, Intellia to its funds (ARKK:BATS) - Seeking Alpha

Oct 06, 2025
pulisher
Oct 06, 2025

How Intellia Therapeutics Inc. (38I) stock performs in easing cyclesQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Citizens upgrades Intellia Therapeutics stock rating on strong HAE outlook - Investing.com

Oct 06, 2025
pulisher
Oct 05, 2025

How Intellia Therapeutics Inc. stock reacts to global recession fearsQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details - MSN

Oct 05, 2025
pulisher
Oct 05, 2025

Intellia Therapeutics shares up after Wolfe upgrade - MSN

Oct 05, 2025
pulisher
Oct 04, 2025

Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought - AOL.com

Oct 04, 2025
pulisher
Oct 04, 2025

Intellia Therapeutics (NTLA) Is Up 22.4% After Promising Phase 1 Data and ARK Investment Buy-In—What's Changed - Sahm

Oct 04, 2025
pulisher
Oct 04, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 04, 2025
pulisher
Oct 03, 2025

Intellia Therapeutics Executive Makes Notable Stock Sale - TipRanks

Oct 03, 2025
pulisher
Oct 03, 2025

Intellia Therapeutics (NASDAQ:NTLA) CAO Sells $32,517.98 in Stock - MarketBeat

Oct 03, 2025

Intellia Therapeutics Inc Stock (NTLA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Intellia Therapeutics Inc Stock (NTLA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Dube Michael P
VP, Chief Accounting Officer
Oct 01 '25
Sale
17.38
1,871
32,518
55,266
CHASE WILLIAM J
Director
Aug 20 '25
Buy
10.03
100,000
1,003,000
134,693
Dulac Edward J III
EVP, Chief Financial Officer
Jul 23 '25
Sale
14.02
7,462
104,617
106,062
Clark Eliana
EVP, Chief Technical Officer
Jul 01 '25
Sale
9.82
1,022
10,036
95,369
Dube Michael P
VP, Chief Accounting Officer
Jul 02 '25
Sale
9.95
2,503
24,905
57,137
GOODMAN JESSE
Director
Jun 30 '25
Sale
9.56
1,547
14,789
25,906
GOODMAN JESSE
Director
Jul 01 '25
Sale
9.23
1,547
14,279
24,359
Bhanji Muna
Director
Apr 29 '25
Sale
8.50
265
2,252
19,203
Clark Eliana
EVP, Chief Technical Officer
Mar 04 '25
Sale
8.99
679
6,104
95,369
BASTA JAMES
EVP, General Counsel
Mar 04 '25
Sale
8.99
2,572
23,122
111,925
$21.35
price down icon 5.74%
$83.80
price down icon 1.12%
$31.81
price down icon 0.13%
$102.06
price down icon 2.32%
$162.33
price down icon 1.26%
biotechnology ONC
$320.10
price down icon 4.68%
Cap:     |  Volume (24h):